This list contains all the current, active, approved protocols for the Kalamazoo Community Clinical Oncology Program—a grant-funded program through the National Cancer Institute—and studies through pharmaceutical companies.

National Cancer Institute approved studies are available through our affiliation with the following research bases: Eastern Cooperative Oncology Group (ECOG), University of Rochester Cancer Center (URCC), University of Texas M.D. Anderson Cancer Center (MDA), National Surgical Adjuvant Breast/Bowel Project (NSABP), Gynecologic Oncology Group (GOG) and Radiation Therapy Oncology Group (RTOG).

If you would like further information on these or other clinical trials, please call the Kalamazoo Community Clinical Oncology Program at (269) 373-7458. For information regarding pediatric studies please call (269) 341-6350.

Ongoing Trials

• Adjuvant Breast Carcinoma ER = Estrogen Receptor, PR = Progesterone Receptor

  TNM Staging: T = Tumor, N = Nodal status, M = Metastasis

  Disease Stage

  Lobular Carcinoma in Situ (LCIS)
  NONE

  Ductal Carcinoma in Situ (DCIS)
  NONE

  Completion of 5 years of Ho…

• Regional & Metastatic Breast Carcinoma ER = Estrogen Receptor, PR = Progesterone Receptor

  Disease Stage
  No Prior Treatment for Metastatic Disease
  Prior Treatment for Metastatic Disease

  Stage IV
  ECOG E1105: Paclitaxel, Carboplatin, and Trastuzumab plus Bevacizumab or Placebo …

• Central Nervous System

  Site
  Protocol Title/Description

  Anaplastic Astrocytoma
  NONE

  Glioblastoma Multiforme

  Recurrent Glioblastoma Multiforme
  MDA 2004-0062: Prior Radiation Therapy within 5 weeks required. Temozolomide (TMZ) versus TMZ plus Thalidomide ve…

• Gastrointestinal System TNM Staging: T = Tumor, N = Nodal Status, M = Metastasis

  Sites
  Adjuvant
  Locally Unrestable
  Metastatic/Measurable

  Esophagus
  Neo-Adjuvant:

  ECOG E2205: Radiation Therapy with Oxaliplatin, continuous infusion 5FU and Cetuximab the surgery…

• Genitourinary System PSA = Prostatic Specific Antigen

  GS = Gleason Score

  TNM Staging: T = Tumor, N = Nodal status, M = Metastasis

  Site
  Stage/Description
  Protocol Title

  Bladder
  Muscle invasive, non-cystectomy candidates
  RTOG 0524: Paclitaxel and trastu…

• Gynecologic

  Site
  Stage/Description
  Protocol Title

  Cervix
  Treated with radical hysterectomy / lymph node dissection
  None

  No prior treatment, limited to the pelvis: Stage IB2, IIA, IIB, IIIB, IVA
  None

  One prior treatment (performance statu…

• Head & Neck TNM Staging: T = Tumor, N = Nodal Status, M = Metastasis

  Site/Type
  Protocol Title

  Resectable
  None

  Oropharyngeal-Advanced squamous cell
  None

  Pathological Stage III/IV

  Preoperative clinical stage may be I-IV and meet specific …

• Leukemia / Lymphoma / Myeloma Hematologic

  LEUKEMIA

  Chronic Myelogenous Leukemia (CML)
  ECOG S0325: Imatinib at 400 mg / day versus Imatinib at 800 mg/day

  Chronic Lymphocytic Leukemia (CLL)-Previously treated, relapsed or refractory
  CTSU C10501: Asymptomatic indivi…

• Lung: Non-Small Cell Lung Cancer and Small Cell Lung Cancer Small Cell Lung Cancer Stage No Prior Treatment Limited RTOG 0623: Cisplatin + Etoposide + Radiation Therapy with growth factor support. CTSU C30610: Radiation therapy plus Cisplatin and Etoposide Locally Advanced NONE Extensive Stage NONE Non-Small Cel…
• Melanoma Melanoma Site/Type Protocol Title Adjuvant Surgical ECOG E1697: Observation versus high dose Interferon (4 wks only) for stage IIA melanoma (T3-4 or N1) Unresectable or Locally Advanced NONE Metastatic ECOG E1602: Multi-epitope Vaccination with Melanom…
• Sarcomas Melanoma Site/Type Protocol Title Adjuvant Surgical ECOG E1697: Observation versus high dose Interferon (4 wks only) for stage IIA melanoma (T3-4 or N1) Unresectable or Locally Advanced NONE Metastatic ECOG E1602: Multi-epitope Vaccination with Melanom…
• Carcinoid / Neuroendocrine Melanoma Site/Type Protocol Title Adjuvant Surgical ECOG E1697: Observation versus high dose Interferon (4 wks only) for stage IIA melanoma (T3-4 or N1) Unresectable or Locally Advanced NONE Metastatic ECOG E1602: Multi-epitope Vaccination with Melanom…
• Symptom Management and Cancer Control Protocols

  Site/Type
  Protocol

  Breast Cancer
  RTOG 0517: Padiopharmaceuticals and Zoledronic acid for bone metastases

  Genetech AVF4349n: Observational study of treatment patterns / safety outcomes

  Cervix
  GOG 221: Pelvic & Para-aortic lymph…